Escientia Biopharma Private Limited, a active private limited company, was established on 22 January 2008 in Hyderabad, Telangana, India. Engaging in pharma contract r&d within the manufacturing sector, it holds CIN: U24100TG2008PTC057277. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹1.50 Cr and a paid-up capital of ₹1.12 Cr.
It upholds a compliant status. Employing 163 professional, Its leadership includes Pendri Kiran Reddy (Director), Dandu Chakradhar (Director), Ajit Alexander George (Director). Past directors included Pendri Kiran Reddy, Dwarakanath Srinivas Rachmadagu, Dandu Chakradhar. Its latest AGM occurred on 20 December 2024, with the balance sheet filed on 31 March 2024. It is based at 1-9-815, Adickmet Near Railway Crossing, Hyderabad, Telangana, 500044.
U24100TG2008PTC057277
057277
22 January 2008
₹1.50 Cr
₹1.12 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Escientia Biopharma Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pendri Kiran Reddy | Director | 10 Nov 2008 | Current |
| Dandu Chakradhar | Director | 19 Aug 2020 | Current |
| Ajit Alexander George | Director | 24 Jun 2023 | Current |
| Varadarajan Purushothaman | Director | 18 Jul 2023 | Current |
| Yadagiri R Pendri | Director | 22 Jan 2008 | Current |
| Suresh Chandra Partani | Director | 22 Jan 2008 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 08 Jul 2009 | Past |
| Pramod Abcsdd | Additional Director | 18 Nov 2020 | Past |
| Pramod Abcsdd | Additional Director | 18 Nov 2020 | Past |
| Pramod Abcsdd | Additional Director | 11 Aug 2023 | Past |
| Pramod Abcsdd | Additional Director | 18 Nov 2020 | Past |
| Pramod Abcsdd | Director | 10 Sep 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Escientia Biopharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 106.2% increase. The company also saw a substantial improvement in profitability, with a 166.27% increase in profit. The company's net worth Soared by an impressive increase of 137.2%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Escientia Biopharma had a promoter holding of 98.81% and a public holding of 1.19%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Escientia Biopharma has a workforce of 163 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Escientia Biopharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Escientia Biopharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Escientia Biopharma Private Limited last Annual general meeting of members was held on 20 Dec 2024 as per latest MCA records. was documented.
Escientia Biopharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad. was recorded as a recent event.
Progress on Varadarajan Purushothaman was appointed as a Director was appointed as a Director on 18 Jul 2023 & has been associated with this company since 2 years 4 months . was documented.
Progress on Ajit Alexander George was appointed as a Director was appointed as a Director on 24 Jun 2023 & has been associated with this company since 2 years 5 months . was documented.
Dandu Chakradhar was appointed as a Director was appointed as a Director on 19 Aug 2020 & has been associated with this company since 5 years 3 months . was recorded as a recent event.
Progress on Vivek Vasant Save was appointed as a Director was appointed as a Director on 19 Aug 2020 & has been associated with this company since 5 years 3 months . was documented.
The CIN of Escientia Biopharma Private Limited is U24100TG2008PTC057277.
Escientia Biopharma Private Limited is headquartered at 1-9-815, Adickmet Near Railway Crossing, Hyderabad, Telangana, 500044.
Escientia Biopharma Private Limited was incorporated on 22 January 2008.
The current directors of Escientia Biopharma Private Limited are
The primary industry of Escientia Biopharma Private Limited is Manufacturing.
Escientia Biopharma Private Limited is unlisted.
The authorized capital of Escientia Biopharma Private Limited is ₹1.50 Cr, and the paid-up capital is ₹1.12 Cr.
The compliance status of Escientia Biopharma Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX